Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.

David R Nelson, Stefan Zeuzem,Pietro Andreone,Peter Ferenci,Robert Herring,Donald M Jensen,Patrick Marcellin,Paul J Pockros,Maribel Rodríguez-Torres,Lorenzo Rossaro,Vinod K Rustgi,Thomas Sepe,Mark Sulkowski,Isaac R Thomason,Eric M Yoshida,Anna Chan,George Hill

Annals of Hepatology（2012）

引用 42|浏览5

暂无评分

摘要

Introduction. Balapiravir (R1626, RG1626) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). This phase 2, double-blind international trial evaluated the optimal treatment regimen of balapiravir plus peginterferon alfa-2a (40KD)/ribavirin.

查看译文

关键词

Chronic hepatitis C,SVR,Safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要